Nintedanib

Cat. No.: HY-50904
CAS No.: 656247-17-5
Molecular Formula: C₃₁H₃₃N₅O₄
Molecular Weight: 539.62
Target: PDGFR; VEGFR; FGFR
Pathway: Protein Tyrosine Kinase/RTK

Storage:
- Powder: -20°C 3 years, 4°C 2 years
- In solvent: -80°C 6 months, -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro
DMSO : 20 mg/mL (37.06 mM; Need ultrasonic and warming)
H₂O : < 0.1 mg/mL (insoluble)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td></td>
<td>1.8532 mL</td>
<td>9.2658 mL</td>
<td>18.5316 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td></td>
<td>0.3706 mL</td>
<td>1.8532 mL</td>
<td>3.7063 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td></td>
<td>0.1853 mL</td>
<td>0.9266 mL</td>
<td>1.8532 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2 mg/mL (3.71 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2 mg/mL (3.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

IC₅₀ & Target

<table>
<thead>
<tr>
<th>IC₅₀ &amp; Target</th>
<th>VEGFR1</th>
<th>VEGFR2</th>
<th>VEGFR3</th>
<th>FGFR1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>34 nM (IC₅₀)</td>
<td>13 nM (IC₅₀)</td>
<td>13 nM (IC₅₀)</td>
<td>69 nM (IC₅₀)</td>
</tr>
<tr>
<td>FGFR2</td>
<td>37 nM (IC₅₀)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FGFR3</td>
<td>108 nM (IC₅₀)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDGFRα</td>
<td>59 nM (IC₅₀)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDGFRβ</td>
<td>65 nM (IC₅₀)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**In Vitro**

Nintedanib (BIBF 1120) binds to the ATP-binding site in the cleft between the amino and carboxy terminal lobes of the kinase domain. Nintedanib (BIBF 1120) inhibits proliferation of PDGF-BB stimulated BRPs with EC$_{50}$ of 79 nM in cell assays. Nintedanib (BIBF 1120) (100 nM) blocks activation of MAPK after stimulation with 5% serum plus PDGF-BB. Nintedanib (BIBF 1120) prevents PDGF-BB stimulated proliferation with an EC$_{50}$ of 69 nM in cultures of human vascular smooth muscle cells (HUASMC)\(^1\).

**In Vivo**

Nintedanib (BIBF 1120) (25-100 mg/kg daily p.o.) is highly active in all tumor models, including human tumor xenografts growing in nude mice and a syngeneic rat tumor model. This is evident in the magnetic resonance imaging of tumor perfusion after 3 days, reducing vessel density and vessel integrity after 5 days, and profound growth inhibition\(^1\). Nintedanib (BIBF 1120) is orally available and displays encouraging efficacy in in vivo tumor models while being well tolerated\(^2\).

**PROTOCOL**

**Kinase Assay**\(^2\)

Enzyme activity is assayed in the presence or absence of serial dilutions of BIBF1120 performed in 25% DMSO. Each microtiter plate contains internal controls such as blank, maximum reaction, and historical reference compound. All incubations are conducted at room temperature on a rotation shaker. 10 μL of each BIBF1120 dilution is added to 10 μL of diluted kinase (0.8 μg/mL VEGFR2, 10 mM Tris pH 7.5, 2 mM EDTA, and 2 mg/mL BSA) and preincubated for 1 hour. The reaction is started by addition of 30 μL of substrate mix containing 62.4 mM Tris pH 7.5, 2.7 mM DTT, 5.3 mM MnCl$_2$, 13.3 mM Mg-acetate, 0.42 mM ATP, 0.83 mg/mL Poly-Glu-Tyr(4:1), and 1.7 μg/mL Poly-Glu-Tyr(4:1)-biotin and incubated for 1 hour. The reaction is stopped by addition of 50 μL of 250 mM EDTA, 20 mM HEPES, pH 7.4. 90 μL of the reaction mix is transferred to a streptavidin plate and incubated for 1-2 hours. After three washes with PBS the EU-labeled antibody, PY20 is added (recommended dilution 1:2000 of 0.5 mg/mL labeled antibody in DELFIA assay buffer). Excessive detection antibody is removed by three ishes of DELFIA washing buffer. Then 10 minutes before measurement on the multilabel reader, each well is incubated with 100 μL of DELFIA enhancement solution.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**Animal Administration**\(^1\)

Five-week-old to 6-wk-old athymic NMRI-nu/nu female mice (21-31 g) are used for the assay. After acclimatization, mice are inoculated with 1 to 5×10$^6$ (in 100 μL) FaDu, Caki-1, SKOV-3, H460, HT-29, or PAC-120 cells s.c. into the right flank of the animal. After acclimatization, F344 Fischer rats are injected with 5×10$^6$ (in 100 μL) GS-9L cells s.c. into the right flank of the animal. For pharmacokinetic analysis, blood is isolated at indicated time points from the retroorbital plexus of mice and plasma is analyzed using high performance liquid chromatography-mass spectrometry methodology.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**CUSTOMER VALIDATION**

- Am J Respir Cell Mol Biol. 2019 Aug 16

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898          Fax: 609-228-5909          E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA